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Abstract: Inhaled corticosteroids (ICS) have proven to be the most effective and essential 
therapy for the treatment of bronchial asthma. The 2007 National Asthma Education and 
Prevention Program guidelines recommend ICS as preferred therapy for patients with mild to 
severe persistent asthma. Mometasone furoate (MF) is a relatively new ICS agent with high 
afﬁ  nity for the glucocorticoid receptor. It is approved in the US for maintenance treatment of 
asthma for patients 4 years of age and older. It has been shown to be well tolerated with no 
signiﬁ  cant adverse side effects observed in clinical trials and post-marketing surveillance. 
The efﬁ  cacy of mometasone furoate has been established in large, well-designed studies. In 
patients with persistent asthma previously treated either with short-acting beta-agonists alone 
or twice-daily maintenance therapy with ICS, once-daily MF has been shown to be superior 
to placebo in improving lung function, symptom control, and quality of life; and has shown 
comparable efﬁ  cacy compared with budesonide, beclomethasone, and ﬂ  uticasone. Twice-daily 
dosing with MF has been demonstrated to successfully allow for reduction or elimination of 
oral corticosteroids in severe asthmatics.
Keywords: inhaled steroids, mometasone furoate, once-daily dosing, asthma, stepwise 
approach
Introduction
Over the past two decades, inhaled corticosteroids (ICS) have been demonstrated to 
be the most effective treatment for persistent asthma. ICS act on the glucocorticoid 
receptor to inhibit the release of cytokines and inﬂ  ammatory mediators, decrease eosin-
ophil and mast cell recruitment, suppress adhesion molecule function and inducible 
nitric oxide synthase (National Heart, Lung and Blood Institute 2007). These cellular 
effects translate clinically into signiﬁ  cant improvements in pulmonary function and 
asthma symptoms as well as reductions in exacerbations requiring oral corticosteroids, 
emergency room care, and hospitalization (National Heart, Lung and Blood Institute 
2007). Further, this class of drugs has been demonstrated to be the most effective 
class of asthma medications compared with other drugs (National Heart, Lung and 
Blood Institute 2007). The most recent National Asthma Education and Prevention 
Program guidelines recommend ICS as preferred therapy for all severity levels of 
asthma (National Heart, Lung and Blood Institute 2007).
Mometasone furoate (MF) is the ﬁ  rst ICS approved for once-daily dosing in the US 
and was approved for patients 12 years and older in 2005 and for children 4 to 11 years 
of age in 2008. It is marketed as Asmanex™ with 110 μg and 220 μg per actuation in a 
multidose dry powder breath-actuated device (Twisthaler™). The 220 μg form delivers 
200 μg of mometasone furoate per actuation while the 110 μg form delivers 100 μg 
mometasone furoate per actuation. The recommended dosages are 220 μg to 440 μg 
once daily in the evening (or in 2 divided doses) for patients 12 years and older previ-
ously treated with either bronchodilators alone or with ICS. The recommended dose for Therapeutics and Clinical Risk Management 2008:4(6) 1202
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patients requiring daily treatment with oral corticosteroids is 
440 μg twice daily. The only recommended dose for children 
4 to 11 years is 110 μg once daily in the evening.
Chemistry
MF is a synthetic, 17-heterocyclic conrticosteroid with a very 
high afﬁ  nity for the glucocorticoid receptor. The chemical 
name of MF is 9α, 21-dichloro-11β,17α-dihydroxy-
16α-methyl-pregna-1,4-diene-3,20-dione17-(2’)-furoate. 
Its molecular formula is C27H30O6Cl2. In vitro studies show 
that MF binds to a monomeric glucocorticoid receptor at low 
concentrations and at high concentrations causes dimerization 
of the glucocorticoid receptor. The receptor afﬁ  nity of MF has 
been estimated to be 12 times that of dexamethasone, 7 times 
that of triamcinolone acetonide, 5 times that of budesonide, 
and 1.5 times that of ﬂ  uticasone (Crim et al 2001).
Pharmacology
MF is extensively metabolized in the liver by the CYP3A4 
enzyme system with only a minor metabolite, 6β-hydroxy-
MF (Affrime and Kosoglu 2001). This metabolite is not 
detectable in plasma after single and multiple doses of 
MF- (dry powder inhaler) DPI, making it unlikely that it 
would affect the hydroxylation of other drugs metabolized 
by CYP3A4 (Karpel and Nelson 2007). In vitro studies have 
demonstrated that there may be as many as 5 metabolites 
and 4 degradation products of MF (Ten et al 2003; Sahas-
ranaaman et al 2006). Study doses were mainly excreted in 
the feces with a small amount in the urine (74 % and 8% 
respectively) (Karpel and Nelson 2007). Pharmacologic 
studies of MF in which a single 1000 μg dose of tritiated 
(3H-) MF was administered by DPI to healthy subjects 
showed that the plasma concentration were below the limit 
of quantiﬁ  cation (LOQ = 50 pg/mL) in 92% of subjects. 
These initial data suggested that the bioavailability of inhaled 
MF is less than 1% (Affrime et al 2000). However, other 
investigations have indicated that the true bioavailability of 
MF is higher and similar in magnitude to that of other ICS 
(Derendorf et al 2002).
In vitro studies have demonstrated that MF has a very 
high binding afﬁ  nity for human glucocorticoid receptor. 
Valotis et al (2004) showed that the relative receptor afﬁ  nity 
for MF is 2200 compared with 100 for dexamethasone and 
1800 for ﬂ  uticasone propionate. In that same study, dis-
sociation of the MF-receptor complex was faster than that 
observed for ﬂ  uticasone, allowing for faster redistribution 
of the drug from lung tissue into the plasma. The relative 
receptor afﬁ  nity of 6-beta-hydorxy MF has been shown to be 
signiﬁ  cantly lower than the parent compound and is similar 
in activity to that of ﬂ  unisolide (206 and 180 for MF and 
ﬂ  unisolide, respectively) (Valotis and Högger 2004).
Clinical efﬁ  cacy (Table 1)
Once-daily dosing in patients only 
on SABAs
Two randomized, double blind studies have conﬁ  rmed the 
efﬁ  cacy of once-daily dosing of MF-DPI compared with 
placebo in steroid-naïve patients only on SABAs.
In a study by Bensch et al (2006), 196 adult and 
adolescent asthmatics were randomized to either MF 200 μg 
once daily in the evening or placebo for 12 weeks. The study 
demonstrated that MF was well tolerated and showed a sig-
niﬁ  cant improvement from baseline FEV1 of  0.43 L (16.8%) 
compared with placebo of 0.16 L ( 6%) (p  0.01). There 
was also signiﬁ  cant improvement in forced vital capacity 
(FVC), forced expiratory ﬂ  ow (FEF) 25% to 75%, and peak 
expiratory ﬂ  ow (PEF) in the treatment group compared with 
placebo. There were no signiﬁ  cant differences between the 
two groups in the time to worsening of asthma. Other efﬁ  cacy 
variables of asthma symptom scores, rescue albuterol use, and 
nocturnal awakenings were also not signiﬁ  cantly different in 
the two groups. The authors felt that the results showed that 
a relatively low dose of MF 200 μg was signiﬁ  cantly better 
than placebo in the steroid-naïve population.
In a second study of 236 steroid-naïve adolescent and 
adult asthmatics by Nayak et al (2000), 2 doses given once 
daily in the morning (200 μg and 400 μg) were compared 
with placebo assessments. The study results showed that 
both doses of MF were well-tolerated. For FEV1, both 
the 200 μg and 400 μg once-daily doses showed superior 
efﬁ  cacy at 14.8% and 14.2% respectively, compared with 
placebo (2.5%) but no signiﬁ  cant difference between each 
other. Most of the secondary efﬁ  cacy variables were signiﬁ  -
cantly improved with both doses compared with placebo. 
An important ﬁ  nding was that the morning PEF was signiﬁ  -
cantly superior to placebo with the 400 μg dose but not with 
the 200 μg dose. The authors suggested that 400 μg should 
be the starting dose with reduction later likely to the 200 μg 
dose (Nayak et al 2000).
Once-daily versus twice-daily dosing 
in patients on SABAs only
In a 12-week study by Kemp et al (2000) with 306 mild to 
moderate asthmatic subjects using inhaled SABAs only, 
MF given once daily (200 μg q AM or 400 μg q AM) or twice Therapeutics and Clinical Risk Management 2008:4(6) 1203
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daily (200 μg bid ) were compared with placebo. There was 
signiﬁ  cant improvement with both the 200 μg bid (16.1%) 
and 400 μg q AM (16.0%) dosing over placebo (5.5%) in 
mean change from baseline in FEV1. However, the 200 μg 
q AM (10.4%) dosing did not show a signiﬁ  cant difference 
from placebo. The secondary efﬁ  cacy variables similarly 
improved signiﬁ  cantly over placebo with a total daily dosing 
of 400 μg, whether given as a qd or bid dosing. All the doses 
were well tolerated.
Once daily versus twice daily dosing 
in patients previously maintained on ICS
Noonan et al (2001) randomized 286 mild to moderate 
asthmatics using twice-daily ICS to receive either MF once 
daily (200 μg q AM, 200 μg q PM or 400 μg q AM ) or 
twice daily (200 μg bid) or placebo for 12 weeks. This was 
preceded by a 2-week open-label phase where all subjects 
received MF 200 μg bid. To obtain data on possible HPA axis 
suppression, cosyntropin stimulation tests were done on 
20 to 24 subjects in each treatment group. Results showed 
that all doses were well tolerated. There was an expected 
increase in the mean baseline FEV1 (2.52 to 2.65 L) after the 
open-label run-in period on MF 200 μg bid. This increase was 
maintained with the 400 μg qd (−0.01), 200 μg bid (−0.03), 
and 200 μg q PM (0.03) doses compared with placebo 
(−0.30). However, the 200 μg q AM dose (−0.22) did not 
do better than placebo, suggesting that evening dosing might 
be more effective. The 400 μg qd dose provided the most 
consistent improvement in the secondary efﬁ  cacy variables. 
The cosyntropin stimulation test results demonstrated that a 
similar proportion of subjects had normal responses in the 
treatment and placebo groups. This study was one of the 
ﬁ  rst to show that once-daily dosing could maintain effective 
control in patients previously on twice-daily dosing.
In a 12-week study with 400 subjects by D’Urzo et al 
(2005), the primary objective was to compare the efﬁ  cacy 
and safety of once-daily MF-DPI 400 μg q PM with placebo. 
A secondary objective was to compare several MF dosing 
regimens with each other and placebo. Subjects were 
all previously on stable bid ICS for at least 30 days and 
were randomized to one of 4 dosing regimens of MF: 200 
μg q PM; 2 inhalations of 200 μg q PM; 200 μg bid; or pla-
cebo. All the MF doses showed signiﬁ  cant improvement over 
placebo with mean changes from baseline FEV1 of 0.41L 
(400 μg q PM), 0.49 L (200 μg 2 inhalations q PM), 0.41L 
(200 μg q PM), 0.51 L (200 μg bid), and 0.16 L ( placebo) 
(p  0.001). All of the treatment doses were well tolerated 
and improved secondary efficacy variables. This study 
conﬁ  rmed the efﬁ  cacy of the 400 μg evening dose, whether 
given as one 400 μg inhalation or two 200 μg inhalations. 
The lowest dose of 200 μg q PM also appeared to be similarly 
effective.
Similar results were obtained in a study of 268 subjects 
by Karpel et al (2005). Patients were 12 years of age or older 
and previously on stable ICS bid for at least 30 days with 
FEV1 between 50% to 85% of predicted. The treatments in 
the study included MF 400 μg q PM, MF 200 μg bid and 
placebo. Both MF doses were well tolerated with mean 
change from baseline FEV1 signiﬁ  cantly improved over 
placebo. The once daily MF 400 μg was as effective as twice 
daily MF 200 μg bid in improving the primary secondary 
efﬁ  cacy measures.
MF in children
Berger et al (2006) published the results of a study of 
MF-DPI in 296 asthmatic children. Children were enrolled 
of 4 to 11 years of age with mild to moderate asthma, 
an FEV1 of 60% to 85% of predicted, and on stable ICS 
doses for at least 60 days. The subjects were random-
ized to receive either 100 μg once daily in the evening, 
100 μg bid, or placebo. The authors indicated that the 
inclusion of a placebo was justiﬁ  ed because patients who 
worsened were to be discontinued and use of short-acting 
beta-agonists was allowed. Both treatment groups showed 
signiﬁ  cant improvement of FEV1 from baseline compared 
with placebo (p  0.002). The least squares mean changes 
in the percentage of predicted FEV1 were 4.73 (MF qd) 
and 5.52 (MF bid) compared with –1.77 (placebo). There 
was no signiﬁ  cant difference in effectiveness between the 
two doses (p = 0.70). FVC, FEF 25% to 75%, and PEF 
were superior for both doses compared with placebo but 
with no signiﬁ  cant difference between the doses. The other 
secondary variables, including asthma symptom scores, 
rescue medication use, and HR QoL assessments all showed 
that the MF groups were similar to each other but superior 
to placebo. Fewer than 50% in the MF treatment groups had 
worsening of asthma so the median time to worsening could 
not be determined. Overall, this study showed the efﬁ  cacy 
and safety of the MF-DPI 100 μg once daily evening dosing 
in children.
Reduction of oral steroids 
in severe asthma
The use of chronic oral corticosteroids (OCS) is necessary 
in a small population of patients with severe asthma. Reduc-
tion or elimination of OCS use is an important goal in these Therapeutics and Clinical Risk Management 2008:4(6) 1204
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Table 1 Clinical studies
Investigators Design Study doses Results
qd, SABA only
Bensch et al 2006 N = 196, 12 week, PC Primary 
outcome: change in FEV1
200 μg q AM Improvement with 200 μg 
(16.8%) vs placebo (6%)
Nayak et al 2000 N = 236, 12 week, PC
Primary outcome: change 
in FEV1
200 μg q AM
400 μg q AM
Both doses better than placebo but 
400 μg provided additional 
improvement
qd vs bid, SABA only
Kemp et al 2000 N = 306, 12 week, PC, Primary 
outcome: change in FEV1
200 μg q AM,
400 μg q AM
200 μg bid
Total of 400 μg/day effective, either 
in qd or bid regimen
Change in FEV1 for 200 μg bid 
(16.1%), 400 μg qd (16.0%) 
signiﬁ  cant over placebo (5.5%)
qd vs bid, previous ICS
Noonan et al 2001 N = 286, 12 week, PC, Primary outcome: 
change in FEV1
200 μg bid,
200 μg q AM,
200 μg q PM,
400 μg q AM
400 μg q am maintained FEV1, lung 
function, symptom scores
200 μg q PM improved FEV1, not 
other measures
200 μg q AM not as effective
D’Urzo et al 2005 N = 400, 12 week, PC, Primary outcome: 
change in FEV1
200 μg QD,
400 μg 1 inhal qd PM
400 μg (2 inhal of 200 μg) qd PM
200 μg bid
All doses better than placebo, 
including lowest dose. Similar 
improvement for all doses
Karpel et al 2005 N = 268, 12 week, PC, Primary outcome: 
change in FEV1
400 μg q PM,
200 μg bid
Both doses better than placebo. 
Similar improvement for all doses
Pediatric
Berger et al 2006 N = 296, 12 week, 4  –11 y.o. 100 μg q AM, 
100 μg bid
Both doses better than placebo. 
Similar improvement for all doses
Reduced oral steroids in severe asthma




OCS reduced by 46% 
(400 μg) , 23.9% (800 μg), 
increased by 164.4% (placebo)
OCS eliminated in 40% (400 μg), 
37% (800 μg) , 0% (placebo)
Lung function and QofL improved





OCS reduced by 39.4% 
(400 μg), 31.1% (800 μg),
increased by 107.2% (placebo)
OCS reduced by 50% 
in 63% (400), 60% (800), 14% (P)
Overall results: (with open 
label extension) 67% OCS 
reduction, 51% OCS elimination
Schmier et al 2003 Open label extension of Fish et al (2000) 400 μg bid
800 μg bid
SF-36 HRQL (QofL) maintained 
or improved for 3 months of open 
label extension
Comparative
Bousquet et al 2000 N = 12 week,   AC Primary outcome: 
change in FEV1
MF 100, 200, 400 μg 
bid, BUD 400 μg bid
MF 200, 400 bid superior to BUD 
400 bid; MF 200 = 400 bid
Conclusion: total 400 μg
MF/day better than 
800 μg BUD/day
(Continued)Therapeutics and Clinical Risk Management 2008:4(6) 1205
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patients and is often employed as the “gold standard” for new 
therapies directed at this severe subgroup of asthmatics.
Fish et al (2000) studied the effect of MF in a 12-week 
study that randomized 132 subjects with severe, OCS-
requiring asthma. The subjects were 12 years of age or older 
who had required daily or alternate-day OCS for asthma 
control for 5 or more of the 6 months before enrollment 
with FEV1 40% to 85% of predicted. The minimum effec-
tive prednisone dose was determined for each subject either 
by previous documentation in the previous 6 months or 
before screening by the investigator who reduced the dose 
in a stepwise manner until pulmonary function declined. 
Subjects receiving a minimum effective prednisone dose 
of 5 to 30 mg daily or 10 to 60 mg every other day were 
eligible for the study. After a 2-week run-in period with 
the subjects continuing their usual ICS and minimum 
effective prednisone dose, they were randomized to either 
MF-DPI 400 μg bid, MF 800 μg bid, or placebo and their 
pre-study ICS was stopped. The primary outcome mea-
sure was the percentage change from baseline in daily 
prednisone requirement. A signiﬁ  cantly larger proportion 
of subjects on placebo (55%) compared with those on MF 
400 μg bid (7%) and MF 800 μg bid (12%) discontinued 
due to treatment failure and worsened asthma. The primary 
outcome measure showed that the MF 400 μg bid (−46%) 
and MF 800 μg bid (−23.9 %) decreased prednisone use 
very significantly compared with placebo (+164.4%) 
(p  0.01). Sixty-two percent of those on MF 400 μg bid 
and 62% of those on 800 μg bid reduced prednisone dose 
by 50% compared with 7 % of the placebo group. Complete 
elimination of prednisone use was seen in 40% of the MF 
400 μg bid group and 37% of the MF 800 μg bid group, 
compared with 0% in the placebo group. Indices of pulmo-
nary function, symptom scores, and QoL measures were 
also improved signiﬁ  cantly in the MF treatment groups 
compared with placebo. The increase in prednisone use 
in the placebo group was expected because the subjects’ 
usual ICS were stopped prior to randomization. The authors 
noted that this observation supported the presence of true 
OCS-dependent asthma in this group. Both MF doses 
were well-tolerated with comparable results between the 
two MF doses leading the authors to conclude that the 
MF 400 μg bid dose is a safe and effective alternative to 
OCS in severe asthma. The steroid-sparing beneﬁ  ts of MF 
were maintained in a 9-month open label extension phase 
(Schmier et al 2003).
Using similar methods and outcome measures, a more 
recent trial studied MF (delivered in the hydroﬂ  uoroalkane 
[HFA]-227 metered dose inhaler [MDI] device) in 
123 OCS-dependent severe persistent asthmatics (Karpel 
et al 2007). Subjects were randomized to receive either 
MF-MDI 400 μg bid, MF-MDI 800 μg bid, or placebo for 
12 weeks followed by a 9-month open label phase. Daily 
prednisone doses were reduced in those on MF-MDI 400 μg 
Table 1 (Continued)
Investigators Design Study doses Results
Chervinsky et al 2002 N = 395, 4 week , PC Dose ranging, Primary 
outcome: change in FEV1
MF-MDI 56, 200, 500 pg 
bid, BDP 168 μg bid
MF 200 pg bid better than MF 56 pg bid 
and BDP 168 μg bid
All doses improved lung function, 
symptom scores, QOL
No additional beneﬁ  t from MF 
500 pg bid
Corren et al 2003 N = 262, 8 week, PC Primary outcome: 
change in FEV1
MF 440 μg q AM
BUD DPI q AM
MF-DPI (8.9%) superior to BUD 
DPI (2.1%) or placebo (−3.9%)
Nathan et al 2001 N = 227, 12 week, PC Primary outcome: 
change in FEV1
MF 100 μg or 200 μg bid 
BDP 168 μg bid
All doses better than placebo
MF 200 μg bid most effective
O’Connor et al 2001 N = 733, 12 week, AC Dose-ranging Pri-
mary outcome: change in FEV1
MF 100,200, or 400 μg bid 
FP diskhaler 250 μg bid
All doses improved outcome
MF 400 μg /day comparable to FP 
500 μg per day
MF 800 μg /day no additional beneﬁ  t. MF 
200 μg /day least effective
Wardlaw et al 2004 N = 167, 8-week, open label, on previous FP 
Primary outcome: change in FEV1
MF 400 μg q PM
FP MDI 250 μg bid
“Comparable efﬁ  cacy” between MF 
(4.58%) and FP (6.98%)
Abbreviations: AC, active controlled; BUD, budesonide; FEV1, forced expiratory volume in 1 second; PC, placebo controlled; FP, ﬂ  uticasone proprionate; MDI, metered dose 
inhaler; MF, mometasone furoate; OCS; chronic oral corticosteroids.Therapeutics and Clinical Risk Management 2008:4(6) 1206
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bid by 39.4 % and 800 μg bid by 31.1% while it increased 
by 107.2% in the placebo group (p  0.01). Oral steroid use 
was reduced by at least 50% in the MF-MDI 400 μg bid, 
MF-MDI 800 μg bid, and the placebo groups by 63%, 60%, 
and 14% respectively. Overall, in the 12-week trial and the 
9-month extension, there was a 67% reduction in prednisone 
requirements and 51% of subjects eliminated oral steroid use 
in those receiving MF-HFA.
Comparison with budesonide (BUD)
In a large active-controlled study by Bousquet et al (2000), 
730 subjects in 17 countries with moderate persistent 
asthma on stable ICS for at least 30 days with FEV1 of 
60% to 90% of predicted, were randomized to one of three 
doses of MF (100 μg bid , 200 μg bid, 400 μg bid) or BUD 
turbohaler 400 μg bid. The results showed signiﬁ  cantly 
superior improvement in the primary efﬁ  cacy variable with 
MF 200 μg bid (0.16 L) and 400 μg bid (0.16 L) compared 
with BUD 400 μg bid (0.06 L), which was comparable with 
the lowest MF dose of 100 μg bid (0.10 L). Secondary param-
eters reﬂ  ected the same results. All the treatment doses were 
well-tolerated. In this study, a total daily dose of MF 400 μg 
appeared to be more effective than a total daily dose of BUD 
800 μg (Bousquet et al 2000).
Once-daily MF was also compared with once-daily BUD 
in a placebo-controlled 8-week study by Corren et al (2003). 
Two hundred and sixty-two subjects with moderate persistent 
asthma previously on stable bid ICS were randomized to 
either MF-DPI 440 μg q AM, BUD-DPI 400 μg q AM, or 
placebo. The primary efﬁ  cacy variable was mean change 
from baseline FEV1. In this study, MF 440 μg q AM showed 
signiﬁ  cantly better improvement in mean percentage change 
in FEV1 (8.9%) compared with BUD 400 μg q AM (2.1%) 
and placebo (–3.9%).
Comparison with beclomethasone 
diproprionate (BDP)
In a 4-week dose-ranging study with 395 subjects, several 
doses of MF given bid by MDI (56 μg, 200 μg, 500 μg) were 
compared with BDP 168 μg bid or placebo (Chervinsky 
et al 2002). Both drugs in this study were delivered in MDI 
devices containing chloroﬂ  uorocarbon vehicle. Subjects with 
moderate asthma, with FEV1 50% to 90%, and stable ICS 
were randomized. All of the ICS treatment groups showed 
signiﬁ  cant improvement of 6% (56 μg MF), 13% (200 μg 
MF), 14% (500 μg MF), and 4% (BDP) compared with 
placebo (−12%). The results suggested that the MF 200 μg 
bid and MF 500 μg bid doses are equivalent with both being 
superior in efﬁ  cacy over the BDP 169 μg bid dose. All doses 
were well tolerated.
A longer, 12-week, placebo-controlled study by Nathan 
et al (2001) enrolled 227 subjects with moderate persistent 
asthma with FEV1 60% to 90% already maintained on ICS 
for at least 30 days. Subjects were randomized to receive 
either MF-DPI 100 μg bid, MF-DPI 200 μg bid, BDP-MDI 
168 μg bid, or placebo. All of the doses were tolerated well. 
With regard to efﬁ  cacy, all of the active groups showed 
signiﬁ  cant improvement in FEV1 over placebo (–0.21 L) 
(p  0.01, all comparisons). However, the MF 200 μg bid 
dose showed a 2-fold improvement (0.25 L) over MF 100 
μg bid (0.12 L) and BDP 168 μg bid (0.11 L). This study 
shows that MF 200 μg bid is more efﬁ  cacious in improving 
lung function and symptom scores compared with MF 100 
μg bid and BDP-MDI 168 μg bid. The authors noted that 
the DPI produces high dose uniformity because it does not 
require hand/breath coordination and that this may contribute 
to better results with the DPI compared with the MDI.
Comparison with ﬂ  uticasone 
proprionate (FP)
A large active-controlled study conducted in 20 countries 
by O’Connor et al (2001), with 732 subjects, compared 
the efﬁ  cacy and safety of MF-DPI with the FP Diskhaler® 
250 μg bid as the active control. Subjects were already 
on stable ICS doses for at least 30 days and had baseline 
FEV1 at 60% to 90% of predicted. Subjects received 
either one of three doses of MF-DPI (100 μg, 200 μg, or 
400 μg bid) or FP Diskhaler 250 μg bid. All MF doses 
and FP improved FEV1 from baseline with a total daily 
dose of MF 200 μg bid dose (0.16 L) comparable with 
FP 500 μg per day (0.16 L). MF 100 μg bid was the least 
effective (0.07 L) while MF 400 μg bid (0.19 L) offered 
no additional beneﬁ  t. Greater improvement was also seen 
in the secondary variables for the MF 200 μg and 400 μg 
bid and FP groups compared with the MF 100 μg bid group 
(O’Connor et al 2001).
Wardlaw et al (2004) conducted an open-label 8 week 
study of 167 subjects with moderate persistent asthma on 
previously stable FP for at least 30 days. Subjects were 
required to have an FEV1 of 60% to 90% of predicted and 
were randomized to receive either MF-DPI 400 μg q PM or 
FP MDI 250 μg (two 125 μg inhalations) bid. Mean changes 
from baseline FEV1 for the MF-DPI and FP groups were 
0.11 L (4.58%) and 0.16 L (6.98%), respectively (p = 0.35). 
Both drugs were well tolerated, with signiﬁ  cantly more 
subjects who “liked the inhaler a lot” in MF-DPI group Therapeutics and Clinical Risk Management 2008:4(6) 1207
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(46.8%) than in the FP group (22.4%) (p = 0.01). This open 
label study conﬁ  rmed comparable efﬁ  cacy between a total 
daily dose on MF 400 μg q PM and FP 500 μg qd.
The most recent comparison between these two inhaled 
compounds was published by Harnest et al (2008). In 
this 12-week non-inferiority trial of patients with moder-
ate-to-severe persistent asthma, there were no signiﬁ  cant 
between-group differences in lung function, rescue medica-
tion use, response to therapy, exacerbation rates, or adverse 
events between MF-DPI 400 μg twice daily or FP-DPI 
500 μg twice daily. Based on these results, these medica-
tions appear to be roughly equivalent in effectiveness on 
a microgram basis.
Safety and tolerability
In general, the potential for side effects from ICS is small 
and the beneﬁ  ts far outweigh any risks (National Heart, Lung 
and Blood Institute 2007). However, local and occasionally 
systemic side effects may occur with ICS, especially at 
high doses. Oral candidiasis can be seen and mouth-rinsing 
after each inhalation should always be strongly advised for 
patients. Systemic effects such as adrenal suppression, cata-
racts, glaucoma, and decreased bone mineral density in adults, 
and adrenal suppression and decreased growth velocity in 
children are possible with high doses of inhaled steroids but 
are much less likely than with oral or parenteral steroids.
In clinical studies in both children and adults, MF has 
been shown to be well tolerated; oral candidiasis was the most 
frequently observed treatment-related adverse event (Meltzer 
et al 2006). Studies of HPA axis suppression have revealed 
only minimal effects by MF. In one study comparing the 
HPA axis effects of MF and FP, the free plasma concentra-
tion producing 50% urinary cortisol suppression (IC50) was 
similar for both compounds indicating the same potential 
to cause systemic side effects (Tayab et al 2007). Adrenal 
suppression as measured by overnight urinary cortisol/cre-
atinine in a study with 21 patients also suggested similar 
signiﬁ  cant suppression by both MF and FP dry powder for-
mulations (Fardon et al 2004). In a study of MF delivered by 
DPI or MDI, doses of up to1600 μg daily for 28 days showed 
minimal HPA axis suppression as measured by serum cortisol 
concentration area under the curve over 24 hours (AUC 24) 
and consyntropin response test (Affrime et al 2000). In a 
study comparing MF-DPI 400 μg qd with beclomethasone 
diproprionate (BDP) HFA 200 μg 2 puffs bid and BDP-CFC 
400 μg 2 puffs bid for 14 days, the serum cortisol AUC24 
decreased to a lesser degree with MF than with the two 
formulations of BDP (Chrousos et al 2005).
Studies of MF effects on bone mineral density (BMD) 
have been conducted for periods up to 2 years in duration. 
At the 2-year endpoint, there was no statistically signiﬁ  cant 
in lumbar spine BMD in patients using 400 μg bid compared 
with a placebo group (Mortimer et al 2005).
Decreases in growth velocity may be observed in children 
taking with ICS but long-term follow-up studies have shown 
that the expected adult heights are usually achieved (Agertoft 
and Pedersen 2000; Gulliver et al 2007). The effect of MF 
on growth in children has been followed for up to 1 year in 
clinical studies (Skoner et al 2003; Lemanske et al 2004). 
In a 1-year study, there was no difference in growth velocity 
between patients taking MF-DPI 100 μg qd (6.42 cm/year) 
and placebo (6.52 cm/year), but a slight but statistically 
signiﬁ  cant difference was observed with patients taking 
200 μg qd (5.82 cm/year).
Conclusion
MF is a potent ICS with strong afﬁ  nity for the glucocorticoid 
receptor. It is currently approved for use in 40 countries 
including the UK and EU down to the age of 4 years. It is 
well tolerated with no signiﬁ  cant adverse side effects seen 
in post-marketing surveillance different from those known 
for ICS as a class. The efﬁ  cacy of MF has been established 
in large, well-designed studies. Once-daily dosing has been 
shown to be as effective as twice daily dosing. In patients with 
persistent asthma on SABA alone, or on previous ICS taken 
twice-daily, MF has been shown to be superior to placebo in 
improving lung function, symptom control and quality of life. 
It has also allowed severe asthmatics to reduce or eliminate 
OCS from their regimen. MF-DPI once-daily has shown 
comparable or better efﬁ  cacy with BDP, BUD, and FP.
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